12 completed, 6 active not recruiting, 2 recruiting, 2 terminated. 11 Phase 3, 8 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Active not recruiting 5, Recruiting 2, Terminated 2, Completed 1, Enrolling by invitation 1 |
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 7 | Completed 6, Active not recruiting 1 |
Follow Xenon Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) Azetukalner - Bipolar Depression, Bipolar I Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 400 | 2025-10-30 | 2026-10-13 |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) Azetukalner, Placebo - Bipolar Disorder, Bipolar Depression | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 400 | 2025-08-08 | 2026-10-13 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2025-07-08 | 2026-10-15 |
| An Open-Label Study of Azetukalner in Major Depressive Disorder Azetukalner - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 460 | 2025-03-18 | 2026-10-13 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2024-12-20 | 2026-10-13 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) XEN1101, Placebo - Focal Onset Seizures | Phase 3 | Recruiting | Xenon Pharmaceuticals Inc. | 360 | 2023-05-09 | 2026-10-08 |
| An Open-label Study of XEN1101 in Epilepsy XEN1101 - Focal Epilepsy, Tonic-Clonic Seizures | Phase 3 | Enrolling by invitation | Xenon Pharmaceuticals Inc. | 880 | 2023-04-25 | 2026-10-08 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures XEN1101, Placebo - Primary Generalized Tonic-Clonic Seizures | Phase 3 | Recruiting | Xenon Pharmaceuticals Inc. | 160 | 2023-02-14 | 2026-10-08 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures XEN1101, Placebo - Focal Onset Seizures | Phase 3 | Completed | Xenon Pharmaceuticals Inc. | 380 | 2022-11-18 | 2026-05-14 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder XEN1101 10 mg, XEN1101 20 mg, Placebo - Major Depressive Disorder | Phase 2 | Completed | Xenon Pharmaceuticals Inc. | 168 | 2022-05-19 | 2026-09-21 |
| An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE XEN496 - Epilepsy, Epilepsy in Children | Phase 3 | Terminated | Xenon Pharmaceuticals Inc. | 8 | 2021-08-17 | 2025-02-14 |
| Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 14C-XEN1101 - Healthy Volunteers | Phase 1 | Completed | Xenon Pharmaceuticals Inc. | 6 | 2021-07-14 | 2022-01-14 |
| XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy XEN496, Placebo - Epilepsy, Epilepsy in Children | Phase 3 | Terminated | Xenon Pharmaceuticals Inc. | 8 | 2021-03-29 | 2024-08-23 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy XEN1101 - Focal Epilepsy | Phase 2 | Active not recruiting | Xenon Pharmaceuticals Inc. | 325 | 2019-01-30 | 2024-09-24 |
| Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 XEN901, Inert Ingredients Oral Product - Healthy Volunteers | Phase 1 | Completed | Xenon Pharmaceuticals Inc. | 70 | 2018-02-19 | 2019-07-22 |
| Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 XPF-008, Microcrystalline Cellulose - Healthy Male Volunteers | Phase 1 | Completed | Xenon Pharmaceuticals Inc. | 20 | 2018-02-13 | 2018-09-18 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101. XPF-008, Microcrystalline Cellulose, XPF-010 - Healthy Volunteers | Phase 1 | Completed | Xenon Pharmaceuticals Inc. | 130 | 2017-11-13 | 2023-05-11 |
| A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel XPF-005, Placebo - Acne Vulgaris | Phase 1 / Phase 2 | Completed | Xenon Pharmaceuticals Inc. | 213 | 2015-09-17 | 2019-01-22 |
| Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia XPF-002, Placebo - Primary Erythromelalgia, Inherited Erythromelalgia | Phase 1 / Phase 2 | Completed | Xenon Pharmaceuticals Inc. | 8 | 2011-12-01 | 2014-04-14 |
| A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) XPF-002, Placebo - Postherpetic Neuralgia | Phase 2 | Completed | Xenon Pharmaceuticals Inc. | 70 | 2010-08-01 | 2013-11-25 |
Showing 20 of 23. Sign in to see all of them.
Epilepsy (7) · Seizures (5) · Depression (4) · Depressive Disorder, Major (4) · Bipolar Disorder (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Disease (2) · Epilepsies, Partial (2) · Epileptic Syndromes (2) · Erythromelalgia (2) · Nervous System Diseases (2) · Acne Vulgaris (1) · Cardiovascular Diseases (1) · Neuralgia, Postherpetic (1)
XEN1101 (9) · ezogabine (2) · microcrystalline cellulose (2) · Itraconazole (1)
United States (16) · Spain (8) · United Kingdom (8) · Germany (7) · Australia (6) · Canada (6) · Italy (6) · Poland (6) · Belgium (5) · Bulgaria (5) · Argentina (4) · Chile (4) · Czechia (4) · Finland (4) · Mexico (4)
Gregory Beatch, PhD (2) · Almena L Free, MD (1) · Gregory N Beatch, PhD (1) · Joost PH Drenth, MD PhD (1) · Richard Larouche, MD (1) · Steven Christensen, DDS (1)
2017 (3), 2009 (1), 2018 (1)